Biogen CEO says he’s concerned about ‘a lot more policy risk’ in D.C.

Running a biotech company means taking risks — deciding where to invest, for example, or what scientific targets to chase.

However, the sector faces another kind of risk, with a new administration in charge in Washington.

That’s the message Biogen chief executive Chris Viehbacher conveyed to Massachusetts Gov. Maura Healey, during a Q&A session following her speech on Thursday at an Associated Industries of Massachusetts event in Waltham. Earlier in the week, the National Institutes of Health and other federal health agencies cancelled a flurry of meetings, as the incoming Trump administration gets settled.